Javascript must be enabled to continue!
Performance of a Divided-Load Intravenous Vancomycin Dosing Strategy for Obese Patients
View through CrossRef
Background: Current guidelines recommend vancomycin trough concentrations of 15 to 20 µg/mL in complicated infections and all trough concentrations >10 µg/mL to avoid developing microbial resistance. To date, no published protocol reliably meets these recommendations for obese patients. Objective: We assessed the performance of a novel, obese-specific, divided-load vancomycin protocol for attaining target trough concentrations within 12 to 24 hours of dosing initiation, and during maintenance dosing, in obese patients. Methods: The protocol was evaluated through prospective medical record review in 54 consecutive obese patients. Vancomycin serum concentrations were drawn before the third and fifth dose after initiation. Steady-state concentrations were drawn after the third dose once maintenance dosing was achieved and periodically thereafter. Results: Within 12 hours after dosing initiation, 48 (89%) study patients exhibited trough concentrations of 10 to 20 µg/mL averaging 14.5 ± 3.2 µg/mL; 51 (94%) study patients exhibited trough concentrations >10 µg/mL within 12 hours after dosing initiation, and 3 (6%) had trough concentrations >20 µg/mL. Thirty-one participants had second trough concentrations drawn within 24 hours of dosing initiation, averaging 15.0 ± 3.1 µg/mL; 24 patients had a total of 32 trough concentrations drawn during maintenance dosing, averaging 15.1 ± 2.5 µg/mL. Conclusion: Obese-specific, divided-load dosing achieved trough concentrations of 10 to 20 µg/mL for 89% of obese patients within 12 hours of initial dosing and 97% of obese patients within 24 hours of initial dosing while preventing doses given during supratherapeutic trough levels; 97% of troughs measured during steady state were within target range.
Title: Performance of a Divided-Load Intravenous Vancomycin Dosing Strategy for Obese Patients
Description:
Background: Current guidelines recommend vancomycin trough concentrations of 15 to 20 µg/mL in complicated infections and all trough concentrations >10 µg/mL to avoid developing microbial resistance.
To date, no published protocol reliably meets these recommendations for obese patients.
Objective: We assessed the performance of a novel, obese-specific, divided-load vancomycin protocol for attaining target trough concentrations within 12 to 24 hours of dosing initiation, and during maintenance dosing, in obese patients.
Methods: The protocol was evaluated through prospective medical record review in 54 consecutive obese patients.
Vancomycin serum concentrations were drawn before the third and fifth dose after initiation.
Steady-state concentrations were drawn after the third dose once maintenance dosing was achieved and periodically thereafter.
Results: Within 12 hours after dosing initiation, 48 (89%) study patients exhibited trough concentrations of 10 to 20 µg/mL averaging 14.
5 ± 3.
2 µg/mL; 51 (94%) study patients exhibited trough concentrations >10 µg/mL within 12 hours after dosing initiation, and 3 (6%) had trough concentrations >20 µg/mL.
Thirty-one participants had second trough concentrations drawn within 24 hours of dosing initiation, averaging 15.
0 ± 3.
1 µg/mL; 24 patients had a total of 32 trough concentrations drawn during maintenance dosing, averaging 15.
1 ± 2.
5 µg/mL.
Conclusion: Obese-specific, divided-load dosing achieved trough concentrations of 10 to 20 µg/mL for 89% of obese patients within 12 hours of initial dosing and 97% of obese patients within 24 hours of initial dosing while preventing doses given during supratherapeutic trough levels; 97% of troughs measured during steady state were within target range.
Related Results
Comparing Actual and Rounded Serum Creatinine Concentration for Assessing the Accuracy of Vancomycin Dosing in Elderly Patients: A Single-Center Retrospective Study
Comparing Actual and Rounded Serum Creatinine Concentration for Assessing the Accuracy of Vancomycin Dosing in Elderly Patients: A Single-Center Retrospective Study
Prescribers often face the challenge of predicting creatinine clearance (CrCl) in elderly patients who are 65 years or older and have serum creatinine (SCr) concentrations below 1 ...
Can local application of vancomycin reduce surgical site infection rate after open lumbar fusion surgery?: A multicenter retrospective cohort study
Can local application of vancomycin reduce surgical site infection rate after open lumbar fusion surgery?: A multicenter retrospective cohort study
Surgical site infection (SSI) after posterior open lumbar fusion (POLF) is a major concern for both surgeons and patients. We sought to explore whether local application of vancomy...
609. Implementation of Bayesian Software for Vancomycin Dosing Integrated into an Electronic Medical Record
609. Implementation of Bayesian Software for Vancomycin Dosing Integrated into an Electronic Medical Record
Abstract
Background
New vancomycin dosing guidelines recommend using a 24-hour area under the curve (AUC) goal of 400-600mg*h/L ...
Controlling the Evolution of Selective Vancomycin Resistance through Successful Ophthalmic Eye-Drop Preparation of Vancomycin-Loaded Nanoliposomes Using the Active-Loading Method
Controlling the Evolution of Selective Vancomycin Resistance through Successful Ophthalmic Eye-Drop Preparation of Vancomycin-Loaded Nanoliposomes Using the Active-Loading Method
Vancomycin is the front-line defense and drug of choice for the most serious and life-threatening methicillin-resistant Staphylococcus aureus (MRSA) infections. However, poor vanco...
S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
Abstract
Background
Lurasidone is once a day oral medication, which could be administered any time of the day, but the relations...
In Vitro Assessment of Vancomycin HCl Compatibility after Coinfusion with a Specialized Amino Acid Formulation
In Vitro Assessment of Vancomycin HCl Compatibility after Coinfusion with a Specialized Amino Acid Formulation
Vancomycin usage at British Columbia's Children's Hospital has increased substantially in the Special Care Nursery as a consequence of a study demonstrating a reduced morbidity and...
2109. Liposomal Amphotericin B-associated Nephrotoxicity in Obese and Non-obese Patients
2109. Liposomal Amphotericin B-associated Nephrotoxicity in Obese and Non-obese Patients
Abstract
Background
Liposomal amphotericin B (L-amb) is an important antifungal agent which exhibits significant rates of dose-d...
Immune-Mediated Thrombocytopenia in Patients Treated with Vancomycin.
Immune-Mediated Thrombocytopenia in Patients Treated with Vancomycin.
Abstract
Numerous drugs are known to cause immune thrombocytopenia (TP) mediated by antibodies (abs) that bind to platelets only when the sensitizing drug is present...

